Next-Generation Cell-Based Therapies to Combat Metastatic Brain Tumor

Glioblastoma (GBM) is a grade IV aggressive type brain tumor that causes rapid proliferation and growth rate. The average survival period is 14 to 16 months after diagnosis and the progression-free survival rate (PFS) is 7 to 10 months. The existing therapies such as radiation, surgical resection, and chemotherapy are not showing curable results due to the development of resistance and the plethora of side effects in the treatment of an advanced brain tumor. To destroy the formidable glioma cells and bring the patient’s outcome, we need to look for a novel therapy that is more advanced and effective against metastatic brain tumor cells. Several cellular-based therapeutic approaches significantly identified the tumor cells and destroyed them by stimulating the host’s innate and adaptive immune system and repressing oncogenic intracellular pathways. Monitoring the therapeutic molecule’s action and patient’s outcome can be done with the help of artificial intelligence (AI). AI is a growing technique used to predict the tumor stage and the therapeutic benefits associated with the treatment. Treating advanced metastatic brain tumors with this cellular therapy and analyzing the patient’s therapeutic outcome using AI might be a promising approach to curing the heterogeneous brain tumor.